1 / 46

Philadephia chromosomal positive acute lymphoblastic leukemia

Philadephia chromosomal positive acute lymphoblastic leukemia. Jiong HU Blood & Marrow Transplantation Center, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine. 1. Role of TKI: overview 2. Dose of chemotherapy with TKI 3. SCT with TKI:

rosemary-mayo
Télécharger la présentation

Philadephia chromosomal positive acute lymphoblastic leukemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Philadephia chromosomal positive acute lymphoblastic leukemia Jiong HU Blood & Marrow Transplantation Center, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

  2. 1. Role of TKI: overview 2. Dose of chemotherapy with TKI 3. SCT with TKI: allo-SCT and pre/post-SCT TKI auto-SCT 4. Elderly

  3. Background about 25% adult cases of ALL randomized controlled trials of therapy unusual poor outcome with standard combination chemotherapy Two major developments tyrosine kinase inhibitors (TKI) myeloablativeallogeneic HSCT

  4. Tyrosine kinase inhibitors (TKI) Khan S. US Pharm. 2012;37(5)(Oncology suppl):3-7 Stock W. Leukemia & Lymphoma, 2010; 51(2): 188-198

  5. Tyrosine kinase inhibitors (TKI) Josep-Maria Ribera Leukemia & Lymphoma, 2012; Early Online: 1–7

  6. Tyrosine kinase inhibitors (TKI) Induction: TKIs added upfront , during or after induction chemotherapy CR rates based on morphology and conventional cytogenetics over 90% with major molecular response of 30 ~50% Consolidation: including TKIs and allogeneic HSCT when possible - Overall outcome 40~60% of patients achieved prolonged remissions significant improve compare to pre-TKI era - No rationale for omitting TKIs from treatment though no data from randomized clinical trials Josep-Maria Ribera Leukemia & Lymphoma, 2012; Early Online: 1–7

  7. 1. TKI in the treatment of ph+ ALL 2. Dose of chemotherapy with TKI 3. SCT with TKI: allo-SCT and pre/post-SCT TKI auto-SCT 4. Elderly

  8. Intensity of chemotherapy in TKI era Reduction of cytotoxic agents or even increasing dose of TKIs early studies for patients not eligible for intensive therapy or SCT due to advanced age TKIs (imatinib or dasatinib) combined with minimal chemotherapy achieved 100% CR without induction fatalities Josep-Maria Ribera Leukemia & Lymphoma, 2012; Early Online: 1–7

  9. TKI + chemotherapy: EWALL study EWALL-Ph-01 Study (2007~2010): 71 pts with median age 69.2 (58-83) and FU of 3.3 years Treatment: Induction: Dasatinib 140mg QD (100mg >70y) + weekly VCR 1mg + DEX 40mg 2 days (20mg >70y) x 4 weeks Consolidation: Dasatinib 100mg/d sequentially with MTX 1g/m² IV d1 (500 mg/m² >70y) + L-ASP 10,000UI/m² IM d2 (5,000 UI/m² >70y) for cycles 1, 3, 5 or cytarabine 1g/m²/12h d1, d3, d5 (500 mg/m² >70y) for cycles 2, 4 and 6. Maintenance: Dasatinib sequentially with 6-MP/MTX every other month and DEX/VCR every 2 months up to 24 months followed by dasatinib alone until relapse or death ASH 2012 abstract

  10. TKI + chemotherapy: EWALL study CR: 67/71 (94%) BCR-ABL/ABL ≤0.1% 54%; undetectable (<4.5 log) 22% RFS(censored at HSCT) and OS(non-censored): 42.7% (26.9-58.5) and 44.7% (31.8-57.5) Safety: 3 pts died in induction; 60 pts (84%) received consolidation and 8 died in CR Relapses: 29 relapsed (median 9 months, range 3-34) and 24 pts died; T315I in 63%; F317L in 7%; V299L in 4% and no mutation in 7% ASH 2012 abstract

  11. TKI + chemotherapy: EWALL study Additional chromosomal abnormality (ACA) at induction and molecular response were prognostic factors ASH 2012 abstract

  12. TKI + chemotherapy: EWALL study - 32 adults Ph+ ALL (18~60 years) with pediatric-based chemo + imatinib CR: 94% Toxicity: III-IV infections, neuropathy, myopathy and liver function abnormalities; major treatment delays and dose reductions Median and 3-year OS: 40.7 months and 53%; Median and 3-year EFS: 30.1 months and 50% Imatinib + pediatric-based regimen results in high response, considerable toxicity and high non-relapse mortality post-HSCT British Journal of Haematology Volume 158, Issue 4, pages 506–514, 2012

  13. TKI + chemotherapy: Graaph-2005 study - Prospective randomized study Patients: 18-60 years untreated Ph+ ALL Induction: arm A (IM-based): IM 800mg on D1-28 + VCR (2mg, D1, 8, 15, 22) + DEX(40mg D1-2, 8-9, 15-16, and 22-23); arm B (IM/HyperCVAD): IM 800mg on D1-14 + HyperCVAD Consolidation: 1 cycle of MTX (1g/m2, D1) + AraC (3g/m2/12h, D2~3) + IM 800mg D1-14 followed by allo-SCT or autologous SCT ASH 2012 abstract

  14. TKI + chemotherapy: Graaph-2005 study Patients:270 randomized and 265 were evaluable (133 arm A, 132 arm B; median age, 47 years; median follow-up, 40 months) ASH 2012 abstract

  15. TKI + chemo: Summary • - Front-line TKIs with chemo yields high response rate • TKI + reduced dose chemo followed by Allo-HSCT and/or Auto-HSCT: • comparable outcome to TKI + intensive chemo • Role of intensified chemo must be reconsidered except for patients not undergoing SCT .

  16. 1. TKI in the treatment of ph+ ALL 2. Dose of chemotherapy with TKI 3. SCT with TKI: allo-SCT and pre/post-SCT TKI auto-SCT 4. Elderly

  17. Role of stem cell transplantation in TKI era • Allogeneic transplantation: • considered as the only curative option in the pre TKI era • searching for suitable donor • transplantation mortality • Autologous transplantation: • usually associated with high relapse rate • limited to patients achieved undetectable transcripts .

  18. Role of stem cell transplantation in TKI era • Impact of TKI on leukemia stem cells (LSC): • imatinib and novel TKIs such as nilotinib and dasatinibas combined with cytotoxic agents improved response, molecular remission and overall outcome • in vitro experiments suggested that TKIs have antiproliferative but no cytotoxic effect on most primitive ALL LSCs • none TKIs in clinical use are able to kill most primitive LSCs • LSCs lead to relapse . World J Stem Cells 2012 June 26; 4(6): 44-52

  19. Role of stem cell transplantation in TKI era Therapy with TKI results in the depletion of cycling leukemia cells without eliminating the Leukemia stem cells (LSCs), then the latter can regenerate the tumor after that therapy is halted. World J Stem Cells 2012 June 26; 4(6): 44-52

  20. Allo-SCT in pre TKI era: International ALL Trial MRC UKALLXII/ECOG2993 267 adult ALL without TKI as front-line therapy Blood August 1, 2008 vol. 112 no. 3 903-909

  21. Allo-SCT in post TKI era: GMALL study • Prospective multicenter GMALL study: 335 newly diagnosed Ph+ ALL • Treatment: imatinib 600mg daily with chemotherapy (different starting time and duration) • CR rate: 85.7~89.4% • For all patients in CR1, 219 patients (66.4%)underwent SCT • 3-year and 7 year OS: 57% and 52% • For patients did not undergo SCTinCR1: • median OS of 9.4 months; 3-year OS 14% SCT inCR1remains the treatment of choice even in patients who achievea good molecular response to initial therapy with TKI and chemo ASH 2010, 147

  22. ph+ALL: allo-HSCT combined with TKI • pre-transplantation TKI • improve CR rate and MRD response • post-transplantation TKI • prevention and treatment of relapse Leukemia & Lymphoma, 2012; Early Online: 1–7

  23. MDACCstudy • Retrospective study: adult 102; pediatric 11- Sib donor(n=60), unrelated (n=40), cord blood (n=12), haplo(n=1) • CR1(n=71),CR2(n=11), NR(n=31) • TKI as front-line therapy n=67；Post-transplantation TKI maintenance n=32 • Median FU: 5 years(1.1-20.4) • OS：CR1 43% vs. other 16%, P=.002 • Pre-transplantation TKI not associated with outcome (uni/mutlivariate analysis) Biology of Blood and Marrow TransplantationVolume 18, Issue 4 , Pages 584-592, 2012

  24. JALSG study • Retrospective analysis between 2002~2005 • 100 newly-diagnosed adult ph+ALL with imatinib + chemo as front-line therapy • 97 CR achieved and 51 received allo-HSCT vs. historical control (n=122) allo-HSCT in CR1 without TKI treatment • - 3-year OS: Imatinib+HSCT65%；control HSCT 44%；P=0.005 • 3-year DFS/3-year RR much improved in Imatinib+HSCT group P=0.005 • TRM not significantly different (P=0.27) Leukemia (2011) 25, 41–47

  25. JALSG study Leukemia (2011) 25, 41–47

  26. Imatinib GRAAPH-2003 Study Biology of Blood and Marrow TransplantationVolume 19, Issue 1 , Pages 150-155, 2013

  27. Imatinib GRAAPH-2003 Study * p=0.001~0.002 In Ph+ ALL, the addition of imatinib to chemo followed by auto or allo-HSCT is associated with an improved long-term outcome. Biology of Blood and Marrow TransplantationVolume 19, Issue 1 , Pages 150-155, 2013

  28. Pre-SCT IM: GMALL study • Treatment: • Arm 1: IM starting between IND and conso 1, then after conso1 (n=51); • Arm 2: IM starting 2ndhalf of IND and throughout conso1 (n=105); • Arm 3: IM starting and throughout conso1 (n=179) until SCT ASH 2010, 147

  29. Pre-SCT IM: GMALL study earlier and prolonged IM is associated with superiortreatment outcomes after SCT ASH 2010, 147

  30. PKU Study • n=82 ph+ALL with allo-HSCT: regimen TBI+Cy or BU-based • 62 pts received post-transplantation Imatinib starting D+70; 10(16.1%) stop due to AEs • - DFS：IM group 81.5% vs. no IM group 33.5% (p=0.000) with the median follow-up of 31 months (range, 2.5-76 months) and 24.5 months (range, 4–72 months) • - Multivariate analysis: post-transplantation Imatinib as independent prognostic factor DFS (p=0.000) and OS (p=0.000) J Hematology Oncology 2012

  31. PKU Study Selection bias: more patients in the non IM group present poor prognostic factor such as severe gut GVHD, pancytopenia. J Hematology Oncology 2012

  32. PKU Study J Hematology Oncology 2012

  33. Post-allo-HSCT TKI: GMALL randomized study ASH 2011 abstract

  34. Post-allo-HSCT TKI: GMALL randomized study • Prophylactic imatinib treatment significantly reduces the molecular relapse after SCT • Both prophylactic / pre-emptive strategies are associated with a low rate of hematologic relapse, durable remissions and excellent long-term outcome • MRD+ prior to and early after SCT in small subset of patients associated with poor prognosis even with post-transplant imatinib ASH 2011 abstract

  35. TKI + allo-HSCT: Summary • Pre-transplantation TKI • TKI improve remission rate and improve MRD response • Pre-transplantation TKI improve post-transplantation outcome remains to be determined • Post-transplantation TKI • Benefit need confirmation in prospective study • Tolerability of post-transplantation TKI • Optimal dose, duration of TKI treatment

  36. Autologous SCT • TKI + sequential chemotherapy would result in significant leukemia cell cytoreductionleading to molecular remission in Ph+ ALL • collection of normal hematopoietic stem cells uncontaminated by residual BCR/ABL+ lymphoblasts • reduce the likelihood of relapse after auto-SCT • Post-transplant maintenance with TKIs

  37. Autologous SCT: CALGB study10001 • 58 ph+ ALL with 3-4 cycels of imatinib (400 mg twice daily) plus sequential chemotherapy followed auto-SCT or allo-SCT from a matched sibling donor by TBI/etoposide based conditioning • 15 allo-SCT from sib donor, 19 atuo-SCT, other from unrelated donors or alternative therapy • Imatinib + chemotherapy resulted RT-PCR negative stem cells: 9/19 complete molecular response(CMR); 4/19 major molecular response (MMR) and 6 not evaluable.  ASH 2012 abstract

  38. Autologous SCT: CALGB study10001 • RT-PCR status (CMR vs. MMR) had no effect on OS or DFS after auto-SCT (P=0.77 for DFS and P=0.50 for OS).  • Day +120 MRD auto-SCT: DFS and OS longer in patients with MMR (n=8) than no MMR (n=6, P=0.045 and P=0.011). • Median follow up of 5.1 years: 9/19 (47%) auto-SCT and 7/15 (47%) allo-SCT remain alive in continuous CR.  • 10 relapsed (8 with auto-SCT and 2 with allo-SCT) • DFS (median, 5.5 vs 4.1 years; P=0.84) and OS (median, 6.0 years vs. not reached at >6 years; P=0.90) similar for auto- or allo-SCT ASH 2012 abstract

  39. Autologous SCT: EBMT study • 171 auto-SCT in CR1 between 1996-2010 • Median patient age 48.3 (19-65) years • Conditioning regimen: TBI (63%) or chemotherapy (37%). • Peripheral blood as source of stem cells in 84% • Median follow-up of 2 years • 2-year OS 45% (+/-4%) and LFS 32% (+/-4%) • RI and NRM 54% (+/-4%) and 13% (+/-3%), • 2-year LFS increased from 22% (1996-2000) to 32% (2001-2006) and 54% (2007-2010) p<0.001 • RI decreased from 65% to 47% and 46% (p=0.01) ASH 2012 abstract

  40. Autologous SCT: EBMT study ASH 2012 abstract

  41. Autologous SCT: summary • In the era of TKIs, auto-SCT may be considered potentially curative option for patients without sibling donors • Advantage: more profound responses achieved with TKIs post-transplant maintenance remains to be determined

  42. 1. TKI in the treatment of ph+ ALL 2. Dose of chemotherapy with TKI 3. SCT with TKI: allo-SCT and pre/post-SCT TKI auto-SCT 4. Elderly

  43. Elderly ph+ ALL • TKI + minimal chemo as induction resulted in high initial response • Post-remission therapy: - Myeloablative SCT not feasible - non-myeloablative or auto-SCT can be considered in fit patients - TKI + chemo

  44. Elderly ph+ ALL: PETHEMA study British Journal of Haematology Volume 159, Issue 4, pages 485–488, November 2012

  45. Elderly ph+ ALL: PETHEMA study - 32 newly diagnosed ph+ ALL - median age 65 (56-82) - Induction response: 26 CR (84%); ED 4 (13%); NR 1 (3%) - Post-remission: death in CR 2/26 (8%), relapse 9/26 (35%), alive in CR1 15/32 (47%) - CR duration: median 37 months (13~43) - Median OS: 22 months - Median EFS: 21 months; 4-year EFS: 38% British Journal of Haematology Volume 159, Issue 4, pages 485–488, November 2012

  46. Conclusions • Use of TKIs resulted in higher CR rate (95~100%) even with minimal chemotherapy • TKI-containing therapy followed by myeloablativeallo-HSCT resulted in long-term survival of 50~60% in young adults; promising results also in non-myeloablative HSCT or alternative donor • Auto-HSCT can be reconsidered in case of profound or complete molecular response without suitable donor • TKI + chemo without SCT: - intensified chemo + TKI considered for young/fit patients - TKI + chemo in elderly remained to be improved • Optimal dose / duration of TKI remained to be determined

More Related